Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Andrés Gomez-de-León, David Gómez-Almaguer, Guillermo J. Ruiz-Delgado & Guillermo J. Ruiz-Arguelles. (2017) Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective. Expert Review of Hematology 10:9, pages 809-819.
Read now
Read now
Alaa Fadhil Alwan. (2015) Rebuttal and response to: “The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?” by Ahmet Emre Eskazan, Muhlis Cem Ar and Teoman Soysal. Leukemia & Lymphoma 56:4, pages 1181-1181.
Read now
Read now
Ahmet Emre Eskazan, Muhlis Cem Ar & Teoman Soysal. (2015) The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?. Leukemia & Lymphoma 56:4, pages 1182-1183.
Read now
Read now
Vikram Mathews. (2014) Generic imatinib: the real-deal or just a deal?. Leukemia & Lymphoma 55:12, pages 2678-2680.
Read now
Read now
Teoman Soysal, Ahmet Emre Eskazan & Muhlis Cem Ar. (2014) Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. Expert Review of Hematology 7:6, pages 697-699.
Read now
Read now
Articles from other publishers (12)
Deepak Goni, Arihant Jain, Charanpreet Singh, Nishant Jindal, Ram Nampoothiri, Aditya Jandial, Deepesh Lad, Alka Khadwal, Gaurav Prakash, Shano Naseem, Neelam Varma & Pankaj Malhotra. (2023) Feasibility of treatment-free remission with generic imatinib. Indian Journal of Medical Research 157:1, pages 87-91.
Crossref
Crossref
Abdülkadir Erçalışkan, Duygu Seyhan Erdoğan & Ahmet Emre Eşkazan. (2021) Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Advances 5:17, pages 3344-3353.
Crossref
Crossref
Maria Gemelli, Elena Maria Elli, Chiara Elena, Alessandra Iurlo, Tamara Intermesoli, Margherita Maffioli, Ester Pungolino, Maria Cristina Carraro, Mariella D'Adda, Francesca Lunghi, Michela Anghileri, Nicola Polverelli, Marianna Rossi, Mattia Bacciocchi, Elisa Bono, Cristina Bucelli, Francesco Passamonti, Laura Antolini & Carlo Gambacorti-Passerini. (2020) Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. BLOOD RESEARCH 55:3, pages 139-145.
Crossref
Crossref
Iman Abou Dalle, Hagop Kantarjian, Jan Burger, Zeev Estrov, Maro Ohanian, Srdan Verstovsek, Farhad Ravandi, Gautam Borthakur, Guillermo Garcia‐Manero, Elias Jabbour & Jorge Cortes. (2019) Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Medicine 8:15, pages 6559-6565.
Crossref
Crossref
Irena Ćojbašić, Lana Mačukanović-Golubović, Miodrag Vučić & Žarko Ćojbašić. (2019) Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up. Clinical Lymphoma Myeloma and Leukemia 19:9, pages e526-e531.
Crossref
Crossref
Meinolf Suttorp, Markus Metzler, Frederic Millot, Hiroyuki Shimada, Deepak Bansal, Adalet Meral Günes, Krzysztof Kalwak, Petr Sedlacek, Andre Baruchel, Andrea Biondi, Nobuko Hijiya, Kirk R. Schultz & Martin Schrappe. (2018) Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients. Pediatric Blood & Cancer 65:12, pages e27431.
Crossref
Crossref
Massimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Claudia Minotto, Davide Griguolo, Luciana Marin, Luca Frison, Fabio D’Amore, Marco Basso, Roberto Sartori, Martina Tinelli, Manuela Stulle, Stefania Fortuna, Angela Bonalumi, Giovanni Bertoldero, Ercole De Biasi, Marco Ruggeri, Gianpietro Semenzato, Renato Fanin, Giovanni Pizzolo, Mauro Krampera & Mario Tiribelli. (2018) Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. Leukemia Research 74, pages 75-79.
Crossref
Crossref
Mervat Mattar, Alaa F. Alwan, Houria Boukhelal, Zoubir Chouffai, Fadi Farhat, Mahmoud Hadipour, Emad Hamada, Mohamed Kadhim Jaffar, Mehran Karimi, Fawaz Al-Kasim, Hayder H. Al-Momen, Ahmad M. Tarawah, Atholl Johnston & Khaled M. Musallam. (2018) On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. European Journal of Internal Medicine 48, pages e40-e41.
Crossref
Crossref
Ahmet Emre Eskazan, Sevil Sadri, Dilek Keskin, Mesut Ayer, Bulent Kantarcioglu, Naciye Demirel, Demet Aydin, Fuat Aydinli, Osman Yokus, Isil Erdogan Ozunal, Selin Berk, Fevzi Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek & Teoman Soysal. (2017) Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. Clinical Lymphoma Myeloma and Leukemia 17:12, pages 804-811.
Crossref
Crossref
Erna Islamagic, Azra Hasic, Sabira Kurtovic, Emina Suljovic Hadzimesic, Lejla Mehinovic, Mirza Kozaric & Amina Kurtovic-Kozaric. (2017) The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 17:4, pages 238-240.
Crossref
Crossref
Y Tony Yang, Sumimasa Nagai, Brian K Chen, Zaina P Qureshi, Akida A Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W Raisch, Oliver Sartor, Terhi Hermanson, Robert C Kane, William J Hrushesky, Joshua J Riente, LeAnn B Norris, Laura R Bobolts, James O Armitage & Charles L Bennett. (2016) Generic oncology drugs: are they all safe?. The Lancet Oncology 17:11, pages e493-e501.
Crossref
Crossref
Ahmet Emre Eskazan & Teoman Soysal. (2015) Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience. Journal of Oncology Pharmacy Practice 22:2, pages 382-384.
Crossref
Crossref